普洛药业头孢地尼胶囊获药品注册证书

Core Viewpoint - Pro Pharmaceutical Co., Ltd. has received a drug registration certificate for Cefdinir capsules from the National Medical Products Administration, indicating a significant development in its product portfolio [1] Group 1: Company Developments - The company’s subsidiary, Zhejiang Pro Pharmaceutical Co., Ltd., is the entity that received the drug registration certificate for Cefdinir capsules [1] - Cefdinir capsules are indicated for infections caused by various bacteria, including Staphylococcus, Streptococcus, and Escherichia coli, among others [1] Group 2: Product Indications - The indications for Cefdinir capsules include infections such as pharyngitis, tonsillitis, acute bronchitis, pneumonia, otitis media, sinusitis, pyelonephritis, cystitis, and gonococcal urethritis [1] - Additional indications cover conditions like pelvic inflammatory disease, intrauterine infections, and various skin and soft tissue infections [1]